Professional Marketing briefs: May 2013

Share this article:
AstraZeneca, J&J enter cancer collaborations
AstraZeneca, J&J enter cancer collaborations

Bristol Myers-Squibb will shut now-subsidiary Amylin's San Diego site by 2014. The closing will affect 420 employees who work in R&D, commercial, manufacturing, corporate and administrative positions. BMS also is merging its Ohio workforce with that of Amylin's, a change that will have an impact on the staff who fill Amylin's 400 in-field sales and medical roles. BMS bought Amylin in August 2012, paying $5.3 billion and assuming $1.7 billion in debt.

AstraZeneca announced 3,900 layoffs in March, which will be spread out over the next three years. Sales and adminis­trative positions are among the jobs to be cut. A spokesman told MM&M the bulk of the losses will be in Europe and that some layoffs were previously known about internally.

Accenture's latest numbers indicate that pitching on a doctor's turf will increasingly mean working with fewer clinician owners, reported Amednews. Accenture found “36% of practicing physicians will hold a practice ownership stake by the end of 2013, a decline from 57% in 2000.” Amednews said to also expect high turnover at these businesses because no ownership stake to sell, means an easier exit.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions